France-based Median Technologies is reporting revenue increases for the third quarter of the 2024 fiscal year, which ended on September 30.
The company reported a quarterly revenue of 6.2 million euros ($6.7 million), second highest ever for Median, up 10.7% versus the same quarter in 2023. Additionally, Median reported a total year-to-date revenue of 17.1 million euros ($18.5 million).
The company highlighted that it is "on track" to file U.S. and European marketing authorization for its eyonis lung cancer screening tool in the first half of 2025. Eyonis is an AI-powered diagnostic device that uses machine learning to help analyze low-dose CT imaging data to diagnose lung cancer at the earliest stages.
Median reported 10.3 million euros ($11.1 million) in external costs as of June 30 compared with 8.9 million euros ($9.6 million) a year before. This reflects an increase in Median’s IT infrastructure costs to support eyonis, the company added.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
